Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Cetuximab may also help cisplatin
work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy,
such as cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving cetuximab together with cisplatin
may be a better way to block tumor growth.
PURPOSE: This phase II trial is studying how well giving cetuximab together with cisplatin
works in treating patients with advanced, persistent, or recurrent cervical cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Gynecologic Oncology Group
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)